KMT2C Rekombinanter Antikörper

KMT2C Rekombinant Antikörper für IF/ICC

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human

Anwendung

IF/ICC

Konjugation

CoraLite® Plus 488 Fluorescent Dye

CloneNo.

240542A2

Kat-Nr. : CL488-83595-4

Synonyme

MLL3, 240542A2, HALR, Homologous to ALR protein, KIAA1506

---

• 

  IF Staining of MCF-7 using CL488-83595-4

  Immunofluorescent analysis of (4% PFA) fixed MCF-7 cells using CoraLite® Plus 488 KMT2C antibody (CL488-83595-4, Clone: 240542A2 ) at dilution of 1:200.

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in IF/ICC: MCF-7-Zellen

Empfohlene Verdünnung

• Immunfluoreszenz (IF)/ICC: IF/ICC : 1:50-1:500

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Produktinformation

CL488-83595-4 bindet in IF/ICC KMT2C und zeigt Reaktivität mit human

• Getestete Reaktivität: human
• Wirt / Isotyp: Kaninchen / IgG
• Klonalität: Rekombinant
• Typ: Antikörper
• Immunogen: KMT2C fusion protein Ag28875
• Vollständiger Name: myeloid/lymphoid or mixed-lineage leukemia 3
• Berechnetes Molekulargewicht: 541 kDa
• GenBank-Zugangsnummer: NM_170606
• Gene symbol: KMT2C
• Gene ID (NCBI): 58508
• Konjugation: CoraLite® Plus 488 Fluorescent Dye
• Excitation/Emission maxima wavelengths: 493 nm / 522 nm
• Form: Liquid
• Reinigungsmethode: Protein-A-Reinigung
• Lagerungspuffer: PBS with 50% glycerol, 0.05% Proclin300, 0.5% BSA
• Lagerungsbedingungen: Bei -20°C lagern. Vor Licht schützen. Nach dem Versand ein Jahr stabil. Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

Lysine (K)-specific methyltransferase 2C (KMT2C, also known as MLL3) belongs to the mixed-lineage leukemia (MLL) family of histone methyltransferases which methylate the histone 3 tail at lysine 4 (H3K4) as part of the complex proteins associated with Set 1 (COMPASS) complex. Although originally identified as oncogenic fusions in leukemia, genome-wide mutation studies have revealed frequent, presumably loss-of-function, mutations in various members of the MLL family, including MLL2/KMT2B, MLL3/KMT2C, and MLL4/KMT2D in a variety of malignancies, particularly solid tumors. Mechanistic studies of KMT2C in normal cells have focused primarily on its role in enhancer regulation by deposition of H3K4me1 marks.